DE69205971D1 - Orale dosierungsform mit verzögerter wirkstoffabgabe für die behandlung von intestinalen krankheiten. - Google Patents
Orale dosierungsform mit verzögerter wirkstoffabgabe für die behandlung von intestinalen krankheiten.Info
- Publication number
- DE69205971D1 DE69205971D1 DE69205971T DE69205971T DE69205971D1 DE 69205971 D1 DE69205971 D1 DE 69205971D1 DE 69205971 T DE69205971 T DE 69205971T DE 69205971 T DE69205971 T DE 69205971T DE 69205971 D1 DE69205971 D1 DE 69205971D1
- Authority
- DE
- Germany
- Prior art keywords
- pct
- granules
- dosage form
- drug
- coated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9103795A GB2253346A (en) | 1991-02-22 | 1991-02-22 | Delayed release oral dosage forms for treatment of intestinal disorders |
PCT/GB1992/000318 WO1992014452A1 (en) | 1991-02-22 | 1992-02-21 | Delayed release oral dosage forms for treatment of intestinal disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69205971D1 true DE69205971D1 (de) | 1995-12-14 |
DE69205971T2 DE69205971T2 (de) | 1996-04-11 |
Family
ID=10690451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69205971T Expired - Lifetime DE69205971T2 (de) | 1991-02-22 | 1992-02-21 | Orale dosierungsform mit verzögerter wirkstoffabgabe für die behandlung von intestinalen krankheiten. |
Country Status (23)
Country | Link |
---|---|
US (1) | US5401512A (de) |
EP (1) | EP0572486B1 (de) |
JP (1) | JP2958116B2 (de) |
KR (1) | KR100220322B1 (de) |
AT (1) | ATE129893T1 (de) |
AU (1) | AU652032B2 (de) |
CA (1) | CA2104686C (de) |
CZ (1) | CZ281792B6 (de) |
DE (1) | DE69205971T2 (de) |
DK (1) | DK0572486T3 (de) |
ES (1) | ES2079183T3 (de) |
FI (1) | FI105255B (de) |
GB (1) | GB2253346A (de) |
GE (1) | GEP19971086B (de) |
GR (1) | GR3018455T3 (de) |
HU (1) | HU219449B (de) |
IE (1) | IE74225B1 (de) |
IL (1) | IL101036A (de) |
IN (1) | IN179089B (de) |
NO (1) | NO307405B1 (de) |
NZ (1) | NZ241687A (de) |
WO (1) | WO1992014452A1 (de) |
YU (1) | YU17892A (de) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69229710T2 (de) * | 1991-11-15 | 2000-03-02 | Kanegafuchi Chemical Ind | Esterbindung enthaltende Polymere für pharmazeutische Zubereitungen |
US5322697A (en) * | 1992-05-28 | 1994-06-21 | Meyer James H | Composition and method for inducing satiety |
US6204243B1 (en) | 1993-09-01 | 2001-03-20 | Novatis Ag | Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis |
GB2292079B (en) * | 1994-08-12 | 1998-07-15 | Flexpharm Ltd | Coated prednisolone preparation for the treatment of inflamatory bowel disease |
US6166024A (en) * | 1995-03-30 | 2000-12-26 | Mayo Foundation For Medical Education And Research | Use of topical azathioprine and thioguanine to treat colorectal adenomas |
US20040018236A1 (en) * | 1995-05-08 | 2004-01-29 | Robert Gurny | Nanoparticles for oral administration of pharmaceutical agents of low solubility |
GB2300807B (en) * | 1995-05-15 | 1999-08-18 | Tillotts Pharma Ag | Oral dosage forms of omega-3 polynunsaturated acids for the treatment of inflammatory bowel disease |
AUPN327695A0 (en) * | 1995-05-30 | 1995-06-22 | Chemeq Pty. Limited | Chemotherapeutic compositions |
US6004581A (en) * | 1995-12-21 | 1999-12-21 | Farmaceutisk Laboratorium Ferring A/S | Modified release oral pharmaceutical composition and method for the treatment of bowel diseases |
US5846983A (en) * | 1996-02-09 | 1998-12-08 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
US5889028A (en) * | 1996-02-09 | 1999-03-30 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
US5908912A (en) * | 1996-09-06 | 1999-06-01 | Ppg Industries Ohio, Inc. | Electrodepositable coating composition containing bismuth and amino acid materials and electrodeposition method |
GB9620709D0 (en) * | 1996-10-04 | 1996-11-20 | Danbiosyst Uk | Colonic delivery of weak acid drugs |
US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
DE19732903A1 (de) | 1997-07-30 | 1999-02-04 | Falk Pharma Gmbh | Pellet-Formulierung zur Behandlung des Intestinaltraktes |
US20090149479A1 (en) * | 1998-11-02 | 2009-06-11 | Elan Pharma International Limited | Dosing regimen |
US20060240105A1 (en) * | 1998-11-02 | 2006-10-26 | Elan Corporation, Plc | Multiparticulate modified release composition |
JP4613275B2 (ja) | 1998-11-02 | 2011-01-12 | エラン ファーマ インターナショナル,リミティド | 多粒子改質放出組成物 |
US20070122481A1 (en) * | 1998-11-02 | 2007-05-31 | Elan Corporation Plc | Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer |
US20090297597A1 (en) * | 1998-11-02 | 2009-12-03 | Gary Liversidge | Modified Release Ticlopidine Compositions |
US6962717B1 (en) | 1999-01-29 | 2005-11-08 | Disphar International B.V. | Pharmaceutical compositions |
ITMI991316A1 (it) * | 1999-06-14 | 2000-12-14 | Cip Ninety Two 92 S A | Composizioni farmaceutiche orali a rilascio modificato di mesalazina |
US20040115134A1 (en) * | 1999-06-22 | 2004-06-17 | Elan Pharma International Ltd. | Novel nifedipine compositions |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
EP2269587A1 (de) | 1999-10-29 | 2011-01-05 | Euro-Celtique S.A. | Hydrocodon-Formulierungen mit gesteuerter Freisetzung |
AU3984101A (en) | 2000-02-24 | 2001-09-03 | Advanced Pharma Inc | Antibiotic and antifungal compositions |
US6730320B2 (en) | 2000-02-24 | 2004-05-04 | Advancis Pharmaceutical Corp. | Tetracycline antibiotic product, use and formulation thereof |
US6667057B2 (en) | 2000-02-24 | 2003-12-23 | Advancis Pharmaceutical Corp. | Levofloxacin antibiotic product, use and formulation thereof |
US6991807B2 (en) * | 2000-02-24 | 2006-01-31 | Advancis Pharmaceutical, Corp. | Antibiotic composition |
US6544555B2 (en) * | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
US6623758B2 (en) | 2000-02-24 | 2003-09-23 | Advancis Pharmaceutical Corp. | Cephalosporin-metronidazole antibiotic composition |
US6663890B2 (en) | 2000-02-24 | 2003-12-16 | Advancis Pharmaceutical Corp. | Metronidazole antibiotic product, use and formulation thereof |
US6627222B2 (en) | 2000-02-24 | 2003-09-30 | Advancis Pharmaceutical Corp. | Amoxicillin-dicloxacillin antibiotic composition |
US6663891B2 (en) | 2000-02-24 | 2003-12-16 | Advancis Pharmaceutical Corp. | Erythromyacin antibiotic product, use and formulation thereof |
US6667042B2 (en) | 2000-02-24 | 2003-12-23 | Advancis Pharmaceutical Corp. | Fluroquinilone antibiotic product, use and formulation thereof |
US6610328B2 (en) | 2000-02-24 | 2003-08-26 | Advancis Pharmaceutical Corp. | Amoxicillin-clarithromycin antibiotic composition |
US6632453B2 (en) | 2000-02-24 | 2003-10-14 | Advancis Pharmaceutical Corp. | Ciprofoxacin-metronidazole antibiotic composition |
US6669948B2 (en) | 2000-02-24 | 2003-12-30 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
US6638532B2 (en) | 2000-02-24 | 2003-10-28 | Advancis Pharmaceutical Corp. | Tetracycline—doxycycline antibiotic composition |
US6565882B2 (en) | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
US7025989B2 (en) * | 2000-02-24 | 2006-04-11 | Advancis Pharmaceutical Corp. | Multiple-delayed released antibiotic product, use and formulation thereof |
IT1318376B1 (it) * | 2000-03-07 | 2003-08-25 | Pharmatec Internat S R L | Forme solide orali a rilascio controllato contenenti mesalazina comeprincipio attivo. |
US6541014B2 (en) * | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
US7074417B2 (en) * | 2000-10-13 | 2006-07-11 | Advancis Pharmaceutical Corporation | Multiple-delayed release anti-viral product, use and formulation thereof |
US20020068078A1 (en) * | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
US7157095B2 (en) * | 2000-10-13 | 2007-01-02 | Advancis Pharmaceutical Corporation | Multiple-delayed release antifungal product, use and formulation thereof |
US7105174B2 (en) * | 2000-10-13 | 2006-09-12 | Advancis Pharmaceutical Corporation | Multiple-delayed release anti-neoplastic product, use and formulation thereof |
AU2738302A (en) | 2000-10-30 | 2002-05-15 | Euro Celtique Sa | Controlled release hydrocodone formulations |
CA2359812C (en) | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
US6887492B2 (en) | 2000-12-14 | 2005-05-03 | Leiner Health Services Corp. | Magnesium plus interactive agent delivery |
US6824559B2 (en) * | 2000-12-22 | 2004-11-30 | Advanced Cardiovascular Systems, Inc. | Ethylene-carboxyl copolymers as drug delivery matrices |
US20020197314A1 (en) * | 2001-02-23 | 2002-12-26 | Rudnic Edward M. | Anti-fungal composition |
FR2830446B1 (fr) * | 2001-10-09 | 2004-02-06 | Univ Pasteur | Composition pharmaceutique destinee a liberer une substance active au niveau du colon |
AR036797A1 (es) | 2001-10-15 | 2004-10-06 | Ferring Bv | Un metodo para preparar una composicion farmaceutica que comprende acido 5-aminosalicilico para utilizar en el tratamiento de colitis ulcerosa y enfermedades de crohn |
US20080220074A1 (en) * | 2002-10-04 | 2008-09-11 | Elan Corporation Plc | Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same |
US20040114368A1 (en) * | 2002-12-13 | 2004-06-17 | Shyu Shing Jy | Light device having rotatable or movable view |
WO2004093883A2 (en) | 2003-04-23 | 2004-11-04 | Ferring B.V. | Sachet for a pharmaceutical composition |
EP1648418A4 (de) * | 2003-07-21 | 2011-11-16 | Middlebrook Pharmaceuticals Inc | Antibiotisches produkt, seine verwendung und formulierung |
AU2004258953B2 (en) * | 2003-07-21 | 2011-02-10 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
CA2533178C (en) * | 2003-07-21 | 2014-03-11 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
JP2007502296A (ja) * | 2003-08-11 | 2007-02-08 | アドバンシス ファーマスーティカル コーポレイション | ロバストペレット |
WO2005016278A2 (en) * | 2003-08-12 | 2005-02-24 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
WO2005023184A2 (en) * | 2003-08-29 | 2005-03-17 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
WO2005027877A1 (en) * | 2003-09-15 | 2005-03-31 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
US7387793B2 (en) | 2003-11-14 | 2008-06-17 | Eurand, Inc. | Modified release dosage forms of skeletal muscle relaxants |
WO2005062898A2 (en) * | 2003-12-24 | 2005-07-14 | Advancis Pharmaceutical Corporation | Enhanced absorption of modified release dosage forms |
GB0403247D0 (en) | 2004-02-13 | 2004-03-17 | Tillotts Pharma Ag | A pharmaceutical composition |
ES2407465T3 (es) | 2004-03-29 | 2013-06-12 | Galpharma Co., Ltd. | Nueva proteína galectina 9 modificada y uso de la misma |
WO2006009602A2 (en) | 2004-06-16 | 2006-01-26 | Tap Pharmaceutical Products, Inc. | Multiple ppi dosage form |
JP2008505124A (ja) * | 2004-07-02 | 2008-02-21 | アドバンシス ファーマスーティカル コーポレイション | パルス送達用錠剤 |
DK2801355T3 (en) | 2004-10-08 | 2015-07-06 | Forward Pharma As | A pharmaceutical composition of controlled release comprising a fumaric acid ester. |
US20060121112A1 (en) * | 2004-12-08 | 2006-06-08 | Elan Corporation, Plc | Topiramate pharmaceutical composition |
US20070298098A1 (en) * | 2005-02-16 | 2007-12-27 | Elan Pharma International Limited | Controlled Release Compositions Comprising Levetiracetam |
ITBO20050123A1 (it) * | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
US20060222700A1 (en) * | 2005-04-05 | 2006-10-05 | Groenewoud Pieter J | Tablet and capsule form of liquid active ingredient |
AU2006235483B2 (en) * | 2005-04-12 | 2010-11-25 | Elan Pharma International Limited | Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection |
US20100136106A1 (en) * | 2005-06-08 | 2010-06-03 | Gary Liversidge | Modified Release Famciclovir Compositions |
US8865197B2 (en) * | 2005-09-06 | 2014-10-21 | Israel Oceanographic And Limnological Research Ltd. | Food formulation for aquatic animals with integrated targeted delivery of bioactive agents |
US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
US8778924B2 (en) * | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
ITMI20061692A1 (it) | 2006-09-05 | 2008-03-06 | Alfa Wassermann Spa | Uso di polioli per ottenere forme polimorfe stabili di rifaximina |
WO2008085484A2 (en) * | 2006-12-28 | 2008-07-17 | Jacobus Pharmaceutical Company, Inc. | Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid |
AU2008310735B2 (en) * | 2007-10-12 | 2013-09-12 | Takeda Pharmaceutical Company Limited | Methods of treating gastrointestinal disorders independent of the intake of food |
PT2493471T (pt) | 2009-10-26 | 2020-01-09 | Borody Thomas J | Nova terapia de combinação entérica |
US10588857B2 (en) | 2012-03-29 | 2020-03-17 | Therabiome, Llc | Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix |
US20140141075A1 (en) | 2012-11-21 | 2014-05-22 | Warner Chilcott Company, Llc | 5-aminosalicylic acid capsule formulation |
US9180104B2 (en) | 2013-03-13 | 2015-11-10 | Tris Pharma, Inc. | Benzonatate modified release solid tablets and capsules |
BR112015021403B1 (pt) | 2013-03-13 | 2023-02-14 | Tris Pharma, Inc | Composição oral sólida antitussígena de liberação modificada compreendendo enzonatato em uma matriz |
CN110075130A (zh) | 2013-03-14 | 2019-08-02 | 塞拉拜姆有限责任公司 | 益生生物和/或治疗剂的靶向胃肠道递送 |
US9763887B2 (en) | 2013-03-15 | 2017-09-19 | Allergan Pharmaceuticals International Limited | Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability |
US20200181649A1 (en) * | 2016-07-14 | 2020-06-11 | University Of Delaware | Hybrid formulation of responsive polymeric nanocarriers for therapeutic and diagnostic delivery |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2021409B (en) * | 1977-05-25 | 1982-09-22 | Fisons Ltd | Pharmaceutical composition |
US4250166A (en) * | 1977-05-27 | 1981-02-10 | Shionogi & Co., Ltd. | Long acting preparation of cefalexin for effective treatments of bacterial infection sensitive to cefalexin |
FR2426477A1 (fr) * | 1978-05-26 | 1979-12-21 | Monsanto Co | Composition de retardement d'incendie comprenant notamment du sulfate d'ammonium et un ether carboxyalkylique ou hydroxyalkylique d'un polygalactomannane |
WO1981002671A1 (en) * | 1980-03-20 | 1981-10-01 | Ferring Farma Lab | Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration |
SE8003805L (sv) * | 1980-05-21 | 1981-11-22 | Haessle Ab | En farmaceutisk beredning med forbettrade utlosningsegenskap |
ZA825384B (en) * | 1981-07-31 | 1983-05-25 | Tillott J B Ltd | Orally administrable pharmaceutical compositions |
DK150008C (da) * | 1981-11-20 | 1987-05-25 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat |
IT1230576B (it) * | 1988-10-20 | 1991-10-28 | Angeli Inst Spa | Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon |
IL92343A0 (en) * | 1988-12-20 | 1990-07-26 | Gist Brocades Nv | Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them |
EP0386967B1 (de) * | 1989-03-10 | 1995-07-12 | Yamanouchi Pharmaceutical Co. Ltd. | Die Wirkstoffabgabe steuerndes Überzugsmaterial für lang wirksame Formulierungen |
JPH0334929A (ja) * | 1989-06-29 | 1991-02-14 | Teikoku Seiyaku Kk | 潰瘍性大腸炎およびクローン病治療用経口投与用組成物 |
US5260071A (en) * | 1989-12-18 | 1993-11-09 | Lemelson Jerome H | Drug units and methods for using same |
JPH064531B2 (ja) * | 1990-06-04 | 1994-01-19 | アイセロ化学株式会社 | 大腸崩壊性硬質カプセル |
-
1991
- 1991-02-22 GB GB9103795A patent/GB2253346A/en not_active Withdrawn
- 1991-02-22 GE GEAP19912613A patent/GEP19971086B/en unknown
-
1992
- 1992-02-21 CZ CS931626A patent/CZ281792B6/cs not_active IP Right Cessation
- 1992-02-21 IE IE920548A patent/IE74225B1/en not_active IP Right Cessation
- 1992-02-21 YU YU17892A patent/YU17892A/sh unknown
- 1992-02-21 AU AU12795/92A patent/AU652032B2/en not_active Ceased
- 1992-02-21 KR KR1019930702488A patent/KR100220322B1/ko not_active IP Right Cessation
- 1992-02-21 EP EP92905384A patent/EP0572486B1/de not_active Expired - Lifetime
- 1992-02-21 WO PCT/GB1992/000318 patent/WO1992014452A1/en active IP Right Grant
- 1992-02-21 DE DE69205971T patent/DE69205971T2/de not_active Expired - Lifetime
- 1992-02-21 JP JP4505041A patent/JP2958116B2/ja not_active Expired - Fee Related
- 1992-02-21 ES ES92905384T patent/ES2079183T3/es not_active Expired - Lifetime
- 1992-02-21 US US08/107,744 patent/US5401512A/en not_active Expired - Lifetime
- 1992-02-21 DK DK92905384.1T patent/DK0572486T3/da active
- 1992-02-21 IL IL10103692A patent/IL101036A/en not_active IP Right Cessation
- 1992-02-21 CA CA002104686A patent/CA2104686C/en not_active Expired - Lifetime
- 1992-02-21 IN IN149DE1992 patent/IN179089B/en unknown
- 1992-02-21 NZ NZ241687A patent/NZ241687A/xx not_active IP Right Cessation
- 1992-02-21 HU HU9302379A patent/HU219449B/hu not_active IP Right Cessation
- 1992-02-21 AT AT92905384T patent/ATE129893T1/de not_active IP Right Cessation
-
1993
- 1993-08-20 FI FI933680A patent/FI105255B/fi not_active IP Right Cessation
- 1993-08-20 NO NO932979A patent/NO307405B1/no not_active IP Right Cessation
-
1995
- 1995-12-19 GR GR950403588T patent/GR3018455T3/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69205971D1 (de) | Orale dosierungsform mit verzögerter wirkstoffabgabe für die behandlung von intestinalen krankheiten. | |
PT825858E (pt) | Capsulas de libertacao dependente do tempo contendo acidos poliinsaturados omega-3 para o tratamento da doenca inflamatoria do intestino | |
NO996116D0 (no) | Filmbelagt tablett for forbedret sikkerhet i oevre gastrointestinale system | |
DE69522729D1 (de) | Arzneimittel zum Wirkstoff - Targetting in den Dickdarm | |
IT1149328B (it) | Composizione farmaceutica per la somministrazione per via orale di composti che debbono essere assorbiti nell'intestino crasso | |
EA023971B1 (ru) | Применение композиции, содержащей покрытые энтеросолюбильной оболочкой цистамин или цистеамин, для лечения цистиноза и способ лечения цистиноза | |
MX9500885A (es) | Preparacion farmaceutica para administracion oral. | |
PL327323A1 (en) | Orally administered 5-asa containing pharmaceutic composition of modified active substance release and method of treating intestinal diseases | |
TH61079A (th) | ยาเม็ดเคลือบฟิล์มสำหรับความปลอดภัยที่ดีขึ้นสำหรับทางเดินกระเพาะลำไส้ตอนบน | |
TH57760B (th) | การลำเลียงยาสู่ลำไส้เล็กและลำไส้ใหญ่โดยใช้แคปซูลชนิด hpmc | |
TH31315B (th) | รูปขนาดใช้ยาทางเภสัชกรรมสำหรับให้ทางปาก ซึ่งประกอบรวมด้วยสารยับยั้บการดึงโปรตอน และ nsaid | |
TH31107B (th) | ยาเม็ดเคลือบฟิล์มสำหรับความปลอดภัยที่ดีขึ้นสำหรับทางเดินกระเพาะลำไส้ตอนบน | |
TH60683B (th) | รูปแบบขนาดยาทางเภสัชกรรมที่มีชั้นเคลือบหลายชั้นสำหรับผลกระทบที่ลดลงของการแตกของชั้นเคลือบ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |